Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$230M |
| 2 |
Johnson & Johnson
JNJ
|
+$205M |
| 3 |
Bank of America
BAC
|
+$163M |
| 4 |
Costco
COST
|
+$162M |
| 5 |
GSK
GSK
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IBM
IBM
|
+$396M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$219M |
| 3 |
GE Aerospace
GE
|
+$156M |
| 4 |
Walt Disney
DIS
|
+$154M |
| 5 |
Amazon
AMZN
|
+$138M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.2% |
| 2 | Healthcare | 13.65% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Consumer Staples | 11.26% |
| 5 | Industrials | 10.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Great Southern Bancorp
GSBC
$885M
| $3.31M | 0.01% |
108,978
-5,622
| -5% | -$160K |
|
|
WBK
1452
DELISTED
Westpac Banking Corporation
WBK
| $3.29M | 0.01% |
+113,301
| New | +$3.46M |
|
|
EDMC
1453
DELISTED
EDUCATION MGMT CORP NEW COM STK (PA)
EDMC
| $3.29M | 0.01% |
325,700
+100
| +0% | +$1.17K |
|
1454
Rigel Pharmaceuticals
RIGL
$789M
| $3.28M | 0.01% |
115,014
+69,480
| +153% | +$2.04M |
|
1455
1-800-Flowers.com
FLWS
$258M
| $3.27M | 0.01% |
604,947
-390,100
| -39% | -$1.98M |
|
|
AMTG
1456
DELISTED
APOLLO RESIDENTIAL MTG INC COM STK
AMTG
| $3.26M | 0.01% |
220,410
-4,390
| -2% | -$65.6K |
|
1457
Mercury Systems
MRCY
$6.58B
| $3.26M | 0.01% |
297,400
-81,835
| -22% | -$818K |
|
|
PSXP
1458
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $3.25M | 0.01% |
+85,746
| New | +$2.83M |
|
1459
Waterstone Financial
WSBF
$383M
| $3.25M | 0.01% |
320,931
+36,783
| +13% | +$366K |
|
1460
Skywest
SKYW
$4.15B
| $3.25M | 0.01% |
218,800
-31,200
| -12% | -$475K |
|
|
CSII
1461
DELISTED
Cardiovascular Systems, Inc.
CSII
| $3.24M | 0.01% |
+94,600
| New | +$2.75M |
|
|
USG
1462
DELISTED
Usg
USG
| $3.24M | 0.01% |
+114,100
| New | +$3.09M |
|
1463
Greenlight Captial
GLRE
$512M
| $3.23M | 0.01% |
95,900
+31,100
| +48% | +$973K |
|
|
ERF
1464
DELISTED
Enerplus Corporation
ERF
| $3.22M | 0.01% |
178,631
+95,623
| +115% | +$1.67M |
|
|
AUQ
1465
DELISTED
AURICO GOLD INC COM
AUQ
| $3.21M | 0.01% |
+878,499
| New | +$3.38M |
|
1466
Virtus Investment Partners
VRTS
$1.13B
| $3.2M | 0.01% |
16,000
-15,300
| -49% | -$2.94M |
|
1467
AngioDynamics
ANGO
$649M
| $3.19M | 0.01% |
186,046
+93,323
| +101% | +$1.44M |
|
1468
Brunswick
BC
$5.31B
| $3.18M | 0.01% |
69,100
-382,700
| -85% | -$17M |
|
1469
First American
FAF
$7.52B
| $3.18M | 0.01% |
112,800
-405,200
| -78% | -$10.5M |
|
|
CHTP
1470
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
| $3.18M | 0.01% |
716,494
+490,799
| +217% | +$1.66M |
|
1471
Alamo Group
ALG
$2.01B
| $3.17M | 0.01% |
52,313
-785
| -1% | -$40.7K |
|
|
EVOL
1472
DELISTED
Evolving Systems, Inc.
EVOL
| $3.16M | 0.01% |
324,699
+135,700
| +72% | +$1.37M |
|
|
LIOX
1473
DELISTED
Lionbridge Technologies
LIOX
| $3.16M | 0.01% |
530,320
+186,520
| +54% | +$937K |
|
1474
MaxLinear
MXL
$7.56B
| $3.15M | 0.01% |
301,500
-89,100
| -23% | -$766K |
|
1475
Spire
SR
$4.88B
| $3.13M | 0.01% |
68,800
+48,200
| +234% | +$2.22M |
|
Similar funds
Jim Simons's Q4 2013 Portfolio in Review
As of Q4 2013, Jim Simons held 3,281 positions worth $41.8B, up 1.3% from $41.2B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons withdrew a net $2.31B in Q4 2013, closing 464 positions and reducing 983 holdings. Its most notable exit was GE Aerospace, an estimated $156M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Pfizer worth $230M.
- Jim Simons's largest Q4 2013 buy was Pfizer: 7,904,832 shares worth $230M.
- Jim Simons added most to Johnson & Johnson in Q4 2013, an estimated $205M increase.
- Jim Simons's biggest Q4 2013 reduction was IBM, cutting an estimated $396M.
- Jim Simons fully exited GE Aerospace in Q4 2013, selling an estimated $156M.
- Jim Simons's ten largest holdings make up 11% of its $41.8B portfolio in Q4 2013.
- Jim Simons opened 498 new positions and closed 464 in Q4 2013.
- Jim Simons's portfolio value rose 1.3% quarter-over-quarter to $41.8B.
Based on Renaissance Technologies's 13F filing for Q4 2013, filed 14 Feb 2014.